Analytical Challenges Facing Autologous Cell Therapies

Here, Omkar Kowlaker, Ph.D., Head of Manufacturing and Supply Chain at NextGen Therapies Consulting at Deloitte discusses both auto and allo and why you would also have the supplier or the vendor sign up to address problematic root causes with your batch-to-batch variability.